Compared to patients without diabetes, those using SGLT2 inhibitors had a trend toward longer time to ADT failure (HR, 0.65; 95% CI, 0.43-1.00; P = .05; Table 2). This evidence concerns the gene SLC5A2 and diabetes mellitus.